Genmab A/S announced today, 15 October 2025, that worldwide net trade sales of DARZALEX, including the subcutaneous product, totaled USD 3,672 million in the third quarter of 2025.
The U.S. market contributed USD 2,088 million, while sales outside the United States accounted for USD 1,584 million. Genmab receives royalties on these worldwide net sales under its exclusive license to Johnson & Johnson.
This announcement underscores continued demand for DARZALEX and reinforces Genmab’s royalty revenue stream, supporting its financial performance and strategic focus on integrated biotechnology.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.